Methotrexate vs Pemetrexed Disodium — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Folate Analog Metabolic Inhibitor

Methotrexate

Brand: JYLAMVO

First FDA approval: 1990-11-01

Folate Analog Metabolic Inhibitor

Pemetrexed Disodium

Brand: Alimta

First FDA approval: 2004-02-04

Lowest NADACAcquisition cost floor across all NDCs

$0.158Per unit

—Per unit

Average NADACAcross all dosage forms and strengths

$134.29Up to $960.29

—

Generic manufacturersActive ANDA holders — FDA Orange Book

1434 total ANDAs filed

1335 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$88.7MFull year

$4.5MFull year

Part D claims (CY24)Total fills, all strengths

3.6M1.0M beneficiaries

3K746 beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$24Per claim, all NDCs

$1,435Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

770Substantial friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

620Limited friction

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

Active shortageSee drug profile

DiscontinuedSee drug profile

Generic availableFDA Orange Book

Yes14 manufacturers

Yes13 manufacturers